title: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.
abstract: The molecular mechanism for the anti-inflammatory action of theophylline is currently unknown, but low-dose theophylline is an effective add-on therapy to corticosteroids in controlling asthma. Corticosteroids act, at least in part, by recruitment of histone deacetylases (HDACs) to the site of active inflammatory gene transcription. They thereby inhibit the acetylation of core histones that is necessary for inflammatory gene transcription. We show both in vitro and in vivo that low-dose theophylline enhances HDAC activity in epithelial cells and macrophages. This increased HDAC activity is then available for corticosteroid recruitment and predicts a cooperative interaction between corticosteroids and theophylline. This mechanism occurs at therapeutic concentrations of theophylline and is dissociated from phosphodiesterase inhibition (the mechanism of bronchodilation) or the blockade of adenosine receptors, which are partially responsible for its side effects. Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of HDAC which is subsequently recruited by corticosteroids to suppress inflammatory genes.
authors.affiliation: Thoracic Medicine, Imperial College School of Science, Technology, and Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, United Kingdom.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ito
authors.forename: Sam
authors.initials: S
authors.lastname: Lim
authors.forename: Gaetano
authors.initials: G
authors.lastname: Caramori
authors.forename: Borja
authors.initials: B
authors.lastname: Cosio
authors.forename: K Fan
authors.initials: KF
authors.lastname: Chung
authors.forename: Ian M
authors.initials: IM
authors.lastname: Adcock
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Barnes
mesh_terms: D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D001483:Base Sequence; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D001993:Bronchodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D018592:Cross-Over Studies; D017931:DNA Primers; D003907:Dexamethasone / Q000494:pharmacology; D004311:Double-Blind Method; D004790:Enzyme Induction; D005786:Gene Expression Regulation / Q000187:drug effects*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics; D006655:Histone Deacetylases / Q000096:biosynthesis*; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D013806:Theophylline / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D001993:Bronchodilator Agents; D017931:DNA Primers; D018836:Inflammation Mediators; D003907:Dexamethasone; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013806:Theophylline; D006655:Histone Deacetylases